Template:Combined injectable contraceptives marketed for clinical use

From blackwiki
Jump to navigation Jump to search

Combined injectable contraceptives marketed for clinical use

Composition Dose Vehicle Brand Names Availability
• Estradiol valerate /
• Norethisterone enantate
5 mg EV
50 mg NETE
Oil solution Chinese Injectable No. 3, Efectimes, Ginediol, Mesigyna, Mesilar, Meslart, Mesocept, Mesygest, Nofertyl, Nofertyl Lafrancol, Noregyna, Norestrin, Norifam, Norigynon, Nostidyn, Sexseg, Solouna Approved in at least 36 countries, including Argentina, the Bahamas, Barbados, Bolivia, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, Egypt, El Salvador, Ghana, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Kenya, Mexico, Nicaragua, Panama, Paraguay, Peru, St. Lucia, Turkey, Uruguay, Venezuela, and Zimbabwe
• Estradiol cypionate /
• Medroxyprogesterone acetate
5 mg EC
25 mg MPA
Microcrystalline aqueous suspension Ciclofem, Ciclofemina, Cyclofem, Cyclofemina, Cyclogeston, Femelin, Femydrol, Gestin, Harmonis, Lunella, Lunelle, Novafem Approved in at least 18 countries, including Bolivia, Brazil, Chile, China, Colombia, Costa Rica, El Salvador, Guatemala, Hong Kong, Indonesia, Malaysia, Mexico, Panama, Peru, Puerto Rico, Thailand, the United States, and Zimbabwe
• Estradiol enantate /
• Algestone acetophenide
a
10 mg E2-EN
150 mg DHPA
Oil solution Acefil, Agurin, Atrimon, Ciclomes, Ciclovar, Ciclovular, Cicnor, Clinomin, Cycloven, Daiva, Damix, Deladroxate§, Deprans, Deproxone, Exuna, Ginestest, Ginoplan, Gynomes, Horprotal, Listen, Luvonal, Neogestar, Neolutin, Nomagest, Nonestrol, Normagest, Normensil, Novular, Oterol, Ovoginal, Patector, Patectro, Perludil, Perlumes, Perlutal, Perlutale, Perlutan, Perlutin, Perlutin-Unifarma, Permisil, Preg-Less, Pregnolan, Primyfar, Progestrol, Protegin, Proter, Seguralmes, Synovular, Topasel, Unigalen, Uno-Ciclo, Vagital Approved in at least 19 countries, including Argentina, Belize, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Hong Kong, Mexico, Nicaragua, Panama, Paraguay, Peru, Portugal, and Spain
5 mg E2-EN
75 mg DHPA
Oil solution Anafertin, Patector NF, Yectames Approved at least 9 countries, including Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, and Spain
10 mg E2-EN
120 mg DHPA
Oil solution Unalmes, Yectuna Approved in at least 3 countries, including Brazil, Chile, and Paraguay
10 mg E2-EN
75 mg DHPA
Oil solution Ova Repos Discontinued (firm was in Spain)
• Estradiol benzoate butyrate /
• Algestone acetophenide
10 mg EBB
150 mg DHPA
Oil solution? Redimen, Soluna, Unijab, Unimens§ Approved in Peru and Singapore
• Estradiol valerate /
• Hydroxyprogesterone caproate
5 mg EV
250 mg OHPC
Oil solution Chinese Injectable No. 1 Approved in China
• Estradiol /
• Megestrol acetate
3.5 mg E2
25 mg MGA
Microcrystalline aqueous suspension Chinese Injectable No. 2, Mego-E Approved in China
• Estradiol cypionate /
• Hydroxyprogesterone caproate
5 mg EC
250 mg OHPC
Oil solution? Sinbios Discontinued (firm was in Mexico)
• Estradiol valerate /
• Estradiol benzoate /
• Hydroxyprogesterone caproate
10 mg EV
1 mg EB
250 mg OHPC
Oil solution? Sin-Ol Discontinued (firm was in Mexico)
Notes: All are given by intramuscular injection once a month. Footnotes: = Discontinued. § = Never marketed. a = Unsorted brand names (doses unknown; for E2-EN/DHPA): Evitas and Femineo. Sources: [1][2][3][4][5][6][7][8][9][10][11][12]

References

  1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; International Agency for Research on Cancer (1 January 1999). Hormonal Contraception and Post-menopausal Hormonal Therapy (PDF). IARC. p. 65. ISBN 978-92-832-1272-0.
  2. Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S (2014). "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control" (PDF). World J Pharm Pharm Sci. 3 (10): 364–392. ISSN 2278-4357.
  3. Pramilla Senanayake; Malcolm Potts (14 April 2008). Atlas of Contraception, Second Edition. CRC Press. pp. 50–. ISBN 978-0-203-34732-4.
  4. Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". J Obstet Gynaecol (Lahore). 4 Suppl 1: S1–34. doi:10.3109/01443619409027641. PMID 12290848.
  5. Garza-Flores J (April 1994). "Pharmacokinetics of once-a-month injectable contraceptives". Contraception. 49 (4): 347–59. doi:10.1016/0010-7824(94)90032-9. PMID 8013219.
  6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 431–. ISBN 978-92-832-1291-1.
  7. Klitsch M (1995). "Still waiting for the contraceptive revolution". Fam Plann Perspect. 27 (6): 246–53. doi:10.2307/2136177. PMID 8666089.
  8. Gallo MF, Grimes DA, Lopez LM, Schulz KF, d'Arcangues C (2013). "Combination injectable contraceptives for contraception". Cochrane Database Syst Rev. 3: CD004568. doi:10.1002/14651858.CD004568.pub3. PMID 23641480.
  9. Harry W. Rudel; Fred A. Kinel (September 1972). "Oral Contraceptives. Human Fertility Studies and Side Effects". In M. Tausk (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. II. Pergamon Press. pp. 385–469. ISBN 978-0080168128. OCLC 278011135.
  10. https://www.drugs.com/international/
  11. Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2082. ISBN 978-0-85369-840-1.
  12. http://www.micromedexsolutions.com/micromedex2/librarian/